Phaseline

Companies › Kailera

Kailera: clinical trials, targets and expected readouts

2 active drug programs in 6 registered trials: 3 Phase 3, 2 Phase 2, 1 Phase 1; Metabolic and endocrine, Genitourinary; next expected readout May 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Ribupatide (KAI-9531)
GLP-1 receptor agonist
GLP1RPhase 3Obesity; Obesity With Diabetes; End Stage Renal DiseaseMay 2027
KAI-7535–Phase 2ObesityJul 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07458269Ribupatide (KAI-9531)Phase 2ObesityMetabolic and endocrineMay 2027
NCT07497880KAI-7535Phase 2ObesityMetabolic and endocrineJul 2027
NCT07793929Ribupatide (KAI-9531)Phase 1End Stage Renal DiseaseGenitourinaryFeb 2028
NCT07284875Ribupatide (KAI-9531)Phase 3ObesityMetabolic and endocrineFeb 2028
NCT07284979Ribupatide (KAI-9531)Phase 3ObesityMetabolic and endocrineMar 2028
NCT07284901Ribupatide (KAI-9531)Phase 3Obesity With DiabetesMetabolic and endocrineMar 2028

From the company's SEC filings

Cash and short-term investments of $1.0bn on 2026-09-30; operating cash outflow about $375m a year; runway about 33 months at that burn, to Jul 2029; 5 of 5 coming phase 2-3 readouts fall inside that runway

Press releases filed as 8-K in the last year:

Specialist investors

Held by 7 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.

Targets

GLP1R (1)

Companies with the same targets

Eli Lilly Novo Nordisk Roche Hangzhou Sciwind Biosciences Hangzhou Zhongmei Huadong Pharmaceutical Hanmi Pharmaceutical Company AstraZeneca Amgen Regeneron Pharmaceuticals Green Valley (Shanghai) Pharmaceuticals

Companies built like this

Chendu DIAO Pharmaceutical Group Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics Beijing QL Biopharmaceutical Hangzhou Sciwind Biosciences Amylyx Pharmaceuticals

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.